Modafiendz is a non-peptide diphenylmethylsulfinylacetamide, specifically an N-methylated, bis(4-fluoro)-ring-substituted analog of modafinil. It is an unapproved research/designer chemical with no marketing authorization in any jurisdiction and no validated human dose. Its closest structural relatives, flmodafinil (CRL-40,940) and fladrafinil (CRL-40,941), are explicitly named as WADA-prohibited S6 stimulants on the 2026 list; Modafiendz itself is not explicitly named but may fall under WADA's generic “similar structure or effect” clause. No human pharmacokinetic, safety, or efficacy studies have been published.
Mechanism of Action
No compound-specific mechanistic study (binding assay, transporter functional assay, or in vivo pharmacodynamic study) naming this exact molecule was located in the peer-reviewed literature. Two dedicated structure-activity relationship papers mapping DAT/NET/SERT binding across ring-halogenated and amide-substituted modafinil analog series do not report data for this specific N-methylamide/bis(4-fluorophenyl)/sulfinyl compound. By structural analogy, modafinil and close analogs act as atypical, comparatively low-potency dopamine transporter (DAT) inhibitors raising extracellular dopamine, but whether Modafiendz shares this mechanism, and at what potency, is unconfirmed.
Research Summary
No human data exists. No ClinicalTrials.gov record, no DrugBank entry, and no INN was found; NCATS Inxight Drugs classifies it only as “Other (designer drug),” racemic, with no approval year. Only two PubMed-indexed publications reference this compound, both analytical/forensic chemistry papers: one validated an LC-HRMS method to screen dietary supplements for modafinil analogs (adrafinil, not Modafiendz, was confirmed present in tested products), and one analyzed heat-induced thermal degradation during GC-MS (relevant to forensic identification). No preclinical pharmacology, toxicology, or efficacy studies in animals have been published.
Verified testing for Modafiendz
Aggregated from 2 lab-verified Certificates of Analysis uploaded directly by labs. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
PubChem Compound Summary for CID 132989661, Modafiendz.
FDA/NIH Global Substance Registration System (GSRS) — MODAFIENDZ, UNII 223VWC34TA.
NCATS Inxight Drugs — MODAFIENDZ, UNII 223VWC34TA.
Development and Validation of an Analytical Method to Identify and Quantitate Novel Modafinil Analogs in Products Marketed as Dietary Supplements. 2025. PMID 39466147.
Frequently asked questions
Has Modafiendz been independently lab-tested?
Disclosed Labs has collected 2 Certificates of Analysis (COA) for Modafiendz from 2 independent testing labs. 1 vendor has submitted material for testing. Products average 99.5% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/modafiendz/testing.
How does Modafiendz work?
No compound-specific mechanistic study (binding assay, transporter functional assay, or in vivo pharmacodynamic study) naming this exact molecule was located in the peer-reviewed literature. Two dedicated structure-activity relationship papers mapping DAT/NET/SERT binding across ring-halogenated and amide-substituted modafinil analog series do not report data for this specific N-methylamide/bis(4-fluorophenyl)/sulfinyl compound. By structural analogy, modafinil and close analogs act as atypical, comparatively low-potency dopamine transporter (DAT) inhibitors raising extracellular dopamine, but whether Modafiendz shares this mechanism, and at what potency, is unconfirmed.
What does the research say about Modafiendz?
No human data exists. No ClinicalTrials.gov record, no DrugBank entry, and no INN was found; NCATS Inxight Drugs classifies it only as “Other (designer drug),” racemic, with no approval year. Only two PubMed-indexed publications reference this compound, both analytical/forensic chemistry papers: one validated an LC-HRMS method to screen dietary supplements for modafinil analogs (adrafinil, not Modafiendz, was confirmed present in tested products), and one analyzed heat-induced thermal degradation during GC-MS (relevant to forensic identification). No preclinical pharmacology, toxicology, or efficacy studies in animals have been published.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs